All In Biotech

Drug Trial Radar · NCT01701401

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/- Ribavirin for 12 and 24 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection.

Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 870 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

870

Actual

Start

Sep 2012

Primary completion

Mar 2014

Study completion Apr 2014

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Oct 5, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) tablets with or without ribavirin (RBV) administered for 12 and 24 weeks in treatment-naive subjects with chronic genotype 1 HCV infection.

Conditions

  • Chronic Hepatitis C Virus

Interventions

  • LDV/SOFDrug

    LDV/SOF 90/400 mg FDC tablet administered orally once daily

  • RBVDrug

    RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12)Time frame: Posttreatment Week 12
  2. Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study DrugTime frame: Up to 24 weeks

Locations

88 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    La Jolla, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Englewood, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Gainesville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Wellington, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Lutherville, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Rochester, Minnesota

  • Site not named

    Saint Paul, Minnesota

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Hillsborough, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Santa Fe, New Mexico

  • Site not named

    Manhasset, New York

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Fayetteville, North Carolina

  • Site not named

    Statesville, North Carolina

  • Site not named

    Winston-Salem, North Carolina

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.